

Bedromed spray

Sublingual spray



Bedromed spray is a pharmaceutical grade cannabinoid formulation derived from Bedrocan's standardised *Cannabis sativa* L. chemovars. Formulated as a nano emulsion, metered dose spray, it is designed to enhance sublingual absorption, improve bioavailability, and reduce pharmacokinetic variability. Bedromed spray provides prescribers with a precise and reproducible cannabinoid delivery system.

Product information



- Optimised mucosal absorption through an **advanced emulsion**.
- Derived from multiple standardised Bedrocan® chemovars to ensure **consistent active ingredient composition**.
- Engineered for **rapid onset** and **improved bioavailability** via a water-soluble formulation.
- Guaranteed pharmaceutical-grade quality through **EU-GMP certified manufacturing**.

Active Substance	Formulation	Content / spray (140 µL)	Starting Material*	Carrier Oil	Shelf Life	Packaging Size
● THC	20 mg/mL	2.8 mg	Bedrocan®	LCT oil in water emulsion	12 months	30 mL
● THC ● CBD	10 mg/mL 10 mg/mL	1.4 mg 1.4 mg	Bedrocan® & Bedrolina®	LCT oil in water emulsion	12 months	30 mL
● CBD	20 mg/mL	2.8 mg	Bedrolina®	LCT oil in water emulsion	12 months	30 mL

● THC only ● Balanced ● CBD only

*) **Bedrocan®**, *Cannabis sativa* L. 'Afina' | **Bedrolina®**, *Cannabis sativa* L. 'Janna'



Medicine status

Bedromed spray is supplied on prescription only, in accordance with the applicable national laws and regulations governing cannabis-based medicinal products in the respective market. Formulations containing THC are subject to controlled substance requirements under the relevant national legislation.



About Bedrocan

Bedrocan is recognised as a pioneer in the production of pharmaceutical-grade medicinal cannabis. Since 2003, Bedrocan has supplied cannabis flower products manufactured to pharmaceutical standards, ensuring quality, safety, and reproducibility for inhalation therapies. To address evolving clinical needs, Bedrocan has expanded its portfolio to include EU-GMP-certified oromucosal dosage forms such as Bedromed drops.

Clinical use

Intended use (emerging clinical evidence): Bedromed spray is supplied under special access provisions as an unapproved oromucosal formulation. Current research on the pharmacological class of THC- and CBD-containing medicine has explored potential effects on pain perception and spasticity across several clinical conditions. Further clinical trials are required to determine the safety and efficacy of Bedromed spray. **Warnings and precautions:** Absolute and relative contraindications apply. Potential for medicine interactions must be considered.

Dosing & titration

More info?
See **Treatment Planning**

Sublingual nano-emulsion spray, administered by a metered-dose pump delivering 140 microlitres (μL) per actuation.

Individualised dose titration

Principle: Start low, go slow. Maximum: 15 sprays/day (up to 42.0 mg THC or CBD).

Starting dose and titration schedule (two-week period, days 1–14)

One (1) spray, depending on formulation, delivers up to 2.8 mg THC and 2.8 mg CBD.

Active Substance	Formulation	Dose Timing		Maximum daily dose
		Starting dose	Morning dose	
THC only	20 mg/mL	1 spray, evening	Before 12 noon, if applicable	15 sprays (= 42.0 mg THC)
Balanced	THC 10 mg/mL CBD 10 mg/mL	1 spray, evening	Before 12 noon, if applicable	15 sprays (= 21 mg THC + 21 mg CBD)
CBD only	20 mg/mL	1 spray, evening	Before 12 noon, if applicable	15 sprays (= 42.0 mg CBD)

Note: Patient-specific dosing must be individualised.

Ordering

Ordering process for pharmacies

You can find ordering details at www.bedrocan.com/order.

The Certificate of Analysis (latest batch) is available from your distributor or pharmacy.

Disclaimer This document is provided to support the clinical decision-making of prescribers and pharmacists. The product has not been granted marketing authorisation; therefore, its safety and efficacy have not undergone formal regulatory evaluation. While every effort has been made to ensure the accuracy of the scientific information available at the time of publication, Bedrocan International makes no representations or warranties regarding clinical outcomes. Prescribers should review all available evidence and use this product in accordance with applicable national regulations, professional standards, and the individual patient's clinical circumstances.

Copyright © 2026 Bedrocan International All rights reserved. No part of this document may be reproduced, distributed or transmitted in any form or by any means, including photocopying, without the prior written consent of Bedrocan International. Date of preparation: May 2026

Contact Bedrocan
info@bedrocan.com
bedrocan.com